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A 2014 hypertension guideline raised goal systolic blood
pressure (SBP) from <140 mm Hg to <150 mm Hg for
adults 60 years and older without diabetes mellitus (DM)
or chronic kidney disease (CKD). The authors aimed to
define the status of hypertension in black adults 60 to
79 years from the National Health and Nutrition Examina-
tion Survey 2005–2012 and provide practical guidance.
Black patients were more often aware and treated
(P≤.005) for hypertension than whites and had higher
rates of DM/CKD (P<.001), similar control to <140/<90 mm
Hg with DM/CKD (P=.59), and lower control without DM/
CKD (<140/<90 mm Hg and <150/<90 mm Hg, P≤.01).
Limited awareness (<30%) and infrequent health care
(>30% 0–1 health-care visits per year) occurred in
untreated black and white hypertensive patients without
DM/CKD and BP ≥140/<90 mm Hg. The literature sug-
gests benefits of treated SBP <140 mm Hg in adults 60 to
79 years without DM/CKD. The International Society of
Hypertension in Blacks recommends: (1) continuing efforts
to achieve BP <140/<90 mm Hg in those with DM/CK, and
(2) identifying hypertensive patients without DM/CKD and
BP ≥140/<90 mm Hg and treat to an SBP <140 mm Hg in
black adults 60–79 years. J Clin Hypertens (Greenwich).
2015;17:252–259. ª 2015 Wiley Periodicals, Inc.
For nearly 30 years, the International Society of Hyper-
tension in Blacks (ISHIB) has provided leadership to
mitigate the very high risk of hypertension-related mor-
bidity and mortality in black people of African descent.1
Specifically, ISHIB has promoted greater recognition,
treatment, and control of hypertension and concomitant
cardiovascular risk factors in blacks.2–4
Hypertension is a growing global problem.5 Yet, the
greatest adverse consequences of hypertension, particu-
larly stroke, heart failure, and end-stage renal disease,
occur in black individuals of African descent.1–4 In the
United States, black-white stroke disparities extend to
prehypertension.6 Several factors likely contribute to
greater population attributable risk of hypertension in
blacks including: (1) higher prevalence of hyperten-
sion,1–4 partially reflecting accelerated transition from
prehypertension to hypertension7; (2) greater prevalence
of stage 2 hypertension blood pressure (BP) ≥160/≥100
mm Hg1–4,8; (3) lower rates of hypertension control1–4;
and (4) higher prevalence of comorbid conditions,
which amplify cardiovascular and renal risk such as
obesity, diabetes mellitus (DM), and albuminuria.3
Greater attention to hypertension treatment and
control in the Hypertension Detection and Follow-Up
Program (HDFP) reduced black-white disparities in
stroke and total mortality.9,10 Secular trends with
improving treatment and control of hypertension and
hypercholesterolemia have likely contributed to absolute
reductions in black-white cardiovascular disparities,
although relative disparities persist.1,11,12 Progress in
reducing incident stroke is linked to better hypertension
control and reductions in population BP.11,13
Many ISHIB members expressed major concerns with
the 2014 self-authorized hypertension guidelines from
the 2014 Hypertension Guideline strongly recommend-
ing that antihypertensive pharmacotherapy among
adults 60 years and older in the general population
(without diabetes or chronic kidney disease [CKD])
commence at SBP ≥150 mm Hg with a treatment goal
<150 mm Hg (strong recommendation–Grade A).14 The
corollary recommendation for the general population
60 years and older without diabetes or CKD stated that
if pharmacotherapy lowers SBP to <140 mm Hg and is
well tolerated, further treatment adjustments are not
required (expert opinion–Grade E).
ISHIB trustees were unanimous in their concerns
with the 2014 guidelines for three reasons. First, each
trustee had observed that recommendations to initiate
treatment among adults 60 years and older with
diabetes or CKD with SBP ≥140 mm Hg and to treat
to <140 mm Hg were being overlooked with errant
focus on goal BP <150/<90 mm Hg for all adults
60 years and older. Second, the expert opinion state-
ment to continue current treatment in adults 60 years
and older who were doing well with SBP <140 mm Hg
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was being ignored and antihypertensive therapy was
being reduced for some older patients with well-
controlled BP. Third, expert opinion recommendations
for treating adults younger than 60 years with SBP
≥140 mm Hg to a goal of <140 mm Hg should have
extended to adults 60 years and older. Studies sup-
porting the expert opinion recommendation to treat
adults younger than 60 years with SBP ≥140 mm Hg to
a target <140 mm Hg also included adults 60 years
and older.14
ISHIB trustees agreed it was important to provide
clear guidance for primary care clinicians who manage
most older non-Hispanic black adults with hyperten-
sion. Since clinical trial data on adults ≥80 years outside
Hypertension in the Very Elderly Trial (HYVET) are
limited, our comments focus on black adults 60 to
79 years old.
ISHIB trustees relied on three sources of information:
(1) characteristics of non-Hispanic black and white
hypertensive adults aged 60 to 79 years without diabe-
tes or CKD and BP ≥140/<90 mm Hg in NHANES
2005–2012, ie, the group most affected by strong
recommendations to begin antihypertensive therapy at
an SBP of ≥150 mm Hg and treat to <150 mm Hg; (2)
achieved SBP and outcomes in completed trials that
included adults aged 60 to 79 years; and (3) various
hypertension guideline statements on BP goals in adults
at various ages.
DEFINING THE STATUS OF HYPERTENSION IN
AFRICAN AMERICANS AGED 60 TO 79 YEARS
Data on self-identified non-Hispanic black and white
adults aged 60 to 79 years in the National Health and
Nutrition Examination Survey (NHANES) 2005–2012
were examined as described.15,16 Traditional hyperten-
sion was defined by SBP ≥140 mm Hg and/or diastolic
BP (DBP) ≥90 mm Hg and/or positive response to “Are
you currently taking medication to lower your BP?”
Untreated, twice-told hypertension was defined by
untreated individuals with a BP <140/<90 mm Hg
who reported a physician told them twice that they had
hypertension.17,18
Hypertension control was defined as a BP <140/<90
mm Hg for adults with diabetes and/or CKD. Hyper-
tension control was assessed at both <140/<90 mm Hg
and <150/<90 mm Hg for adults 60 to 79 years without
diabetes and/or CKD.14,16 Diabetes mellitus was defined
by individuals reportedly being informed by a physician
that they had diabetes, according to fasting glucose
≥126 mg/dL or glycosylated hemoglobin ≥6.5%.19
Cardiovascular disease was defined as a composite of
coronary heart disease (CHD), stroke, and congestive
heart failure.20,21 CKD was defined by an estimated
glomerular filtration rate (eGFR) <60 mL/1.73 m2/min
and/or a urine albumin creatinine ratio ≥300 mg/g,22 ie,
values previously used to define a systolic blood pressure
goal <130 mm Hg. Serum creatinine values were
adjusted to facilitate comparisons of eGFR across
surveys.23
Medical visits were defined by responses to “How
many times did you receive health care over the last
year?” Responses were classified into <2 vs ≥2 visits per
year. Uninsured status was defined by a negative answer
to “Are you covered by health insurance or some other
kind of health-care plan?” Cigarette smoker was defined
if a patient answered “every day” or “some days” to
“Do you now smoke cigarettes?” Atherosclerotic (AS)
CVD 10-year risk scores were calculated for black and
white adults 60 to 79 years who were free of clinical
CVD.24
Data Analysis
SAS survey procedures (SAS Institute Inc, Cary, NC)
were used to account for NHANES complex survey
design. PROC SURVEYMEANS was used to generate
means and standard errors. PROC SURVEYFREQ was
used to calculate proportions and standard errors.
PROC SURVEYLOGISTIC was used to assess relation-
ships between clinical variables and untreated and
uncontrolled hypertension. Taylor linearization was
used for variance estimation and domain analysis was
used for subpopulation analysis, since selection of
subpopulations may be unrelated to sample design.
For within-survey between-group comparisons, Rao-
Scott chi-square test was used to test for differences in
categorical variables. The Wald F test was used to assess
differences in continuous variables. P values ≤.05 were
considered statistically significant.
SURVEY OF THE RELEVANT LITERATURE
Several hypertension trials relevant to SBP targets in
older adults were reviewed.13,14,25–35 Several guideline
statements referenced in the 2014 Hypertension Guide-
lines and the American Heart Association/American
College of Cardiology and the American Society of
Hypertension/International Society of Hypertension
statements were reviewed.3,14,36–40
KEY OBSERVATIONS IN OLDER BLACK AND
WHITE ADULTS WITH HYPERTENSION
Among adults 60 to 79 years with hypertension, blacks
had a smaller proportion of men, fewer lean and more
obese patients, and were more likely to be uninsured
than whites (Table I). Blacks had higher SBP values,
were more likely to be aware of and treated for
hypertension, were more likely to have diabetes and
smoke cigarettes, and had higher 10-year atherosclerotic
cardiovascular disease risk than whites. The two groups
did not differ by age, frequency of health-care visits,
DBP, BP control to <140/<90 mm Hg (all hyperten-
sives), treatment for hypercholesterolemia, CKD, or
cardiovascular disease.
When BP control was defined as <140/<90 mm Hg for
patients with diabetes and/or CKD and <150/<90 mm
Hg in adults without diabetes and/or CKD, whites were
more likely than blacks to meet target values. Black and
white adults had similar proportions with hypertension
when traditionally defined as on treatment and/or SBP
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≥140 mm Hg and/or DBP ≥90 mm Hg and when
defined as twice told of hypertension but untreated with
nonhypertensive BP on examination. SBP was higher in
blacks than whites treated for hypertension, and DBP
was not different. In adults with controlled BP, SBP and
DBP were similar in the two race groups.
Table I provides comparisons of black and white
adults 60 to 79 years without diabetes or CKD who had
BP ≥140/<90 mm Hg. Among all black adults 60 to
79 years with hypertension, 16.0% were in this group
vs 21.6% of white adults. In those on treatment, blacks
had higher SBP than whites. In the untreated group,
blacks were more likely to be aware of hypertension
than whites, although the majority of both groups was
unaware.
Figure 1 shows hypertension control in four groups of
black and white adults 60 to 79 years. Hypertension
control did not differ between blacks and whites when
all hypertensive adults (53.5% vs 56.5%, P=.15) or only
those with diabetes and/or CKD were examined (56.6%
vs 58.3%, P=.59). Black adults without diabetes and/or
CKD were less likely than their white counterparts to
have hypertension controlled to <140/<90 mm Hg
(48.9% vs 55.6%, P=.01) and to <150/<90 mm Hg
(66.9% vs 75.3%, P=.002).
Figure 2 depicts multivariable odds ratios (ORs) and
95% confidence intervals (CIs) for various clinical
predictors of uncontrolled hypertension. Data are pro-
vided for all adults 60 to 79 years with hypertension,
only those with diabetes and/or CKD and only those
TABLE I. Description of Black and White Hypertensive Adults Aged 60 to 79 Years: NHANES 2005–2012
Group Black White P Value
NHANES, No. 1038 1719
US population, No. 3,115,288 20,574,110
er, %a 11.61.1 76.41.7
Age, y 68.00.2 68.40.1 .07
Male sex, % 40.01.6 46.51.1 .001
BMI, kg/m2 31.30.2 30.10.2 <.001
BMI, kg/m2
<25, % 18.31.2 19.71.3 <.001
≥30, % 53.31.8 44.81.3
Visits per y, % <2 12.01.3 14.41.1 .14
≥2 88.01.3 85.61.1
Uninsured, % 7.31.0 3.70.5 <.001
Hypertension variables
tHT, % 97.30.5 97.00.6 .65
ntHT, % 2.70.5 3.00.6 .65
SBP, mm Hg (all) 138.40.8 135.10.6 .001
DBP, mm Hg (all) 70.10.7 69.10.5 .16
Aware, % 90.21.0 84.71.0 <.001
Taking BP medication, % 83.01.2 78.21.1 .005
SBP, mm Hg (on Rx) 136.00.8 131.50.5 <.001
DBP, mm Hg (on Rx) 69.00.7 67.50.5 .07
Controlled <140/90, % 53.51.8 56.51.3 .15
SBP, mm Hg (controlled) 122.90.5 121.90.4 .10
DBP, mm Hg (controlled) 65.80.6 65.00.5 .27
Controlled <150/<90, %b 61.11.7 68.51.3 <.001
Other CVD risk factor data
Non-HDL, mg/dL, % 135.51.5 141.81.1 .002
Cholesterol medication, % 41.31.5 44.41.3 .13
Smoker, % 18.51.6 11.10.9 <.001
DM, % 47.01.7 27.71.4 <.001
CKD, % 22.11.5 20.71.0 .42
DM and/or CKD, % 56.41.9 40.01.2 <.001
CVD, % 29.21.5 26.01.5 .08
ASCVD10 y, % 23.90.7 21.10.4 <.001
Abbreviations: ASCVD10 y, estimated 10-year risk for atherosclerotic cardiovascular disease; BMI, body mass index; CKD, chronic kidney disease; CVD,
cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; NHANES, National Health and Nutrition Examination Survey; Rx,
medication; SBP, systolic blood pressure. Data are presented as mean and standard error. aPercentage of all adults 60 to 79 years by race group with
hypertension defined as taking treatment and blood pressure (BP) ≥140/≥90 mm Hg (tHT) or twice-told untreated adults with BP on examination <140/
<90 mm Hg (nHT). bPercentage of all adults 60 to 79 years by race group with BP controlled to <140/<90 mm Hg if diabetes mellitus (DM) and/or chronic
kidney disease (CKD) and to <150/<90 mm Hg if no DM or CKD.
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without DM and/or CKD, and for the latter group not
achieving <150/<90 mm Hg. Black race was associated
with uncontrolled hypertension except among adults
with diabetes and/or CKD. Health-care visit frequency
≥2 times per year was associated with reduced likeli-
hood of uncontrolled hypertension among all hyperten-
sive adults 60 to 79 years and those without diabetes or
CKD when the target of <140/<90 mm Hg was
assessed. Insurance status was not associated with
uncontrolled hypertension.
Figure 3 provides multivariable ORs and 95% CIs for
factors associated with untreated hypertension. Black
race, increasing BMI, CKD, and CVD were associated
with lower probability of untreated hypertension.
Infrequent health care (<2 visits per year) and uninsured
status were associated with greater probability of
untreated hypertension.
SUMMARY OF THE RELEVANT LITERATURE
Six randomized controlled trials on stage 2 isolated
systolic hypertension (BP ≥160/<90–95 mm Hg) are
FIGURE 1. Means and standard errors depict blood pressure (BP) control (<140/<90 mm Hg unless designated) in various groupings of black
and white adults aged 60 to 79 years, including: all patients, only adults with diabetes mellitus (DM) and/or chronic kidney disease (CKD), only
adults without DM and/or CKD, and only adults without DM and/or CKD with goal <150/<90 mm Hg. *P=.01, †P=.002. BMI indicates body mass
index; CVD, cardiovascular disease.
FIGURE 2. Multivariable odds ratios (ORs) and 95% confidence
intervals (CI) depicting the relationship of various modifiable and
nonmodifiable factors on uncontrolled hypertension in black and
white adults aged 60 to 79 years. These relationships are provided
for all patients combined (<140/<90 mm Hg), for patients with and
without diabetes mellitus (DM) and/or chronic kidney disease (CKD)
(<140/<90 mm Hg), and for adults without DM or CKD (<150/<90).
Relationships between clinical variables and uncontrolled
hypertension are considered significant when 95% confidence limits
do not cross the line of identity (1.0).
FIGURE 3. Multivariable odds ratios (ORs) and 95% confidence
intervals (CIs) depicting the relationship of various modifiable and
nonmodifiable clinical variables to untreated hypertension in black
and white adults aged 60 to 79 years. Relationships between clinical
variables and untreated hypertension are considered statistically
significant when 95% CIs do not cross the line of identity (1.0). DM
indicates diabetes mellitus; CKD, chronic kidney disease.
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summarized in Table S1. All four placebo-controlled
trials demonstrated benefit of active treatment on
composite cardiovascular events.25–29 Neither of two
studies comparing target SBP <140 mm Hg with higher
values showed benefit on composite cardiovascular
events,30,31 although these studies were powered to
detect relatively large differences of ≥25%.
Two randomized clinical trials of systolic/diastolic
hypertension that included adults 60 to 79 years are
summarized in Table S2. The Felodipine Event Reduc-
tion (FEVER) study32 documented a 27% reduction in
the primary outcome of stroke (27%) with a 4/2-mm
Hg lower BP vs the comparison group. The Usual vs
Tight Control of Systolic Blood Pressure in Nondiabetic
Patients With Hypertension (Cardio-SIS)33 trial showed
a 37% decrease in electrocardiographic left ventricular
hypertrophy with a 4/2-mm Hg lower BP vs the
comparison group. The secondary composite cardiovas-
cular event outcome was also reduced 50%. A statisti-
cally significant 19% reduction in recurrent stroke was
seen in the Secondary Prevention of Small Subcortical
Strokes (SPS3) with an 11-mm Hg lower SBP among
patients assigned to <130 mm Hg vs 130 mm Hg to
149 mm Hg target.34 In the Perindopril Protection
Against Recurrent Stroke Study (PROGRESS), recurrent
stroke was reduced with perindopril and indapamide
combined, which lowered BP 12/5 mm Hg vs placebo
but not with perindopril alone, which reduced BP 5/3
mm Hg.35
BP goals are summarized for adults younger than 60
years, 60 to 79 years, and 80 years and older and for
adults with diabetes and CKD from various guideline
statements (Table S3).14,36–40 Because adults with dia-
betes and/or CKD were not the focus of this report, the
American Diabetes Association and Kidney Disease
Improving Global Outcomes (KDIGO) guidelines were
not included.41,42
COMMENTARY AND RECOMMENDATIONS ON
THE MANAGEMENT OF HYPERTENSION IN
AFRICAN AMERICANS AGED 60 TO 79 YEARS
ISHIB trustees have concerns related to misinterpreta-
tion of the 2014 Hypertension Guideline and the
recommendation to begin treatment at an SBP
≥150 mm Hg rather than ≥140 mm Hg in adults
60 years and older without diabetes or CKD.14 Our
comments and recommendation focus predominantly
on African American adults 60 to 79 years with
hypertension. Discussion of complex issues in adults
80 years and older exceeds the scope of this
report.29,43,44
Five comments are provided based on key observa-
tions derived from the NHANES analysis of hyperten-
sion in black and white adults 60 to 79 years with
hypertension. Three recommendations are provided
from the literature and guidelines review in response
to the 2014 Hypertension Guideline. All comments and
recommendations focus mainly on black adults of
African descent aged 60 to 79 years with hypertension.
Discussion of complex issues in adults 80 years and
older exceeds the scope of this report.29,43,44
Observation 1: Hypertension control to <140/
<90 mm Hg is similar in black and white adults aged
60 to 79 years with DM and/or CKD (Figure 1).
Comment 1: Adults with diabetes and CKD and those
of African descent are more likely to have uncontrolled
treatment-resistant hypertension than adults without
these factors.45 Thus, it is commendable that clinicians
are achieving BP control in more than 50% of all black
adults aged 60 to 79 years with hypertension and DM/
CKD to <140/<90 mm Hg and achieving comparable
control among black and white adults in this group. To
improve hypertension control further, clinicians are
referred to the outline for antihypertensive pharmaco-
therapy in the 2010 consensus report on management of
hypertension in blacks.3
Observation 2: The disparity in hypertension control
to <140/<90 mm Hg between black and white adults 60
to 79 years is evident in the group without diabetes or
CKD.
Comment 2: The same pharmacotherapy guidance in
comment 1 for patients with DM/CKD applies to
patients with uncontrolled hypertension but without
DM/CKD except that a calcium antagonist or diuretic is
recommended as initial therapy, either alone or together
with a renin-angiotensin system blocker.3
Of importance, in the untreated group with BP ≥140/
<90 mm Hg without DM/CKD, approximately 70% of
black adults are unaware of their hypertension, and
nearly half are seen less than twice annually (Table I).
Infrequent health care and lack of awareness, while
disproportionately a concern for younger adults,16 is
also seen in a substantial subset of older adults with
untreated isolated systolic hypertension. For older
adults with infrequent health care, it is important to
enlist this group in regular care, identify hypertension,
and engage them in effective management with phar-
macotherapy when needed.
Observation 3: DM alone and with CKD are much
more prevalent in non-Hispanic black than white adults
60 to 79 years with hypertension.
Comments 3: Equity in cardiovascular and renal
health equity is impossible when large disparities in
major vascular risk factors persist, since treatment
typically does not fully eliminate excess risk. The good
news is that lifestyle changes including a weight loss of
approximately 4 kg and walking 30 minutes daily most
days of the week were at least as effective for preventing
diabetes in black as white adults and in adults 60 years
years and older as in younger adults in the Diabetes
Prevention Program.46 Clinicians are encouraged to
recommend and support these lifestyle changes in
African Americans at risk for diabetes across the adult
age span.
Observation 4: Mean BP values achieved in all black
adults 60 to 79 years with hypertension are lower than
BP achieved in major trials on isolated systolic hyper-
tension.25–28 Moreover, mean BP values achieved in
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black adults 60 to 79 years who are controlled to <140/
<90 mm Hg are below the values achieved in the
majority of clinical trials including groups that were
more aggressively treated.29–35
Comment 4: Among black and white adults 60 to
79 years who are controlled to <140/<90 mm Hg, mean
BP values of 123/66 mm Hg in blacks and 122/65 mm
Hg in whites are not significantly different. Moreover,
the mean BP values, while well below the <140/<90 mm
Hg goal, are in the range associated with greater stroke
protection.34,47,48
Observation 5: Black adults 60 to 79 years with
hypertension are more likely to smoke cigarettes than
their white counterparts (Table II).
Comment 5: Smoking is a major risk factor for
stroke, ischemic heart disease, and peripheral vascular
occlusive disease. Clinicians providing care for older
African Americans are encouraged to identify those
who smoke cigarettes and support smoking cessation
efforts. Special attention to smoking cessation is
especially important for African Americans with
diabetes as they have more lower-extremity amputa-
tions than Caucasians with diabetes.49 Smoking
cessation interventions for African Americans should:
(1) challenge misconceptions about the safety of
smoking menthol cigarettes that “taste good” and
mask smoking irritation, (2) prepare high-nicotine
smokers for quitting with nicotine-fading and band-
switching techniques, and (3) emphasize relapse pre-
vention, active stress reduction, and cultural meanings
of smoking.50
Recommendation 1: When diabetes and/or CKD are
present, initiate treatment for patients with an SBP
≥140 mm Hg and treat to a goal of <140 mm Hg
including in adults aged 60 to 79 years.
We are concerned that some adults in this group
and their clinicians have overlooked the fourth and
fifth recommendations in the 2014 Hypertension
Guideline and are initiating treatment at a systolic
blood pressure ≥150 mm Hg and treating to a goal of
<150 mm Hg in older adults with diabetes or CKD.
For older adults, a systolic blood pressure target
<140 mm Hg remains reasonable and is associated
with greater protection against stroke and other
cardiovascular outcomes than higher targets.11,13,48,51
In a representative US civilian sample of non-Hispanic
black adults 60 to 79 years with hypertension who
attained BP <140/<90 mm Hg, their mean BP was
123/66 mm Hg (Table II), ie, lower BP is achievable
and relatively well tolerated.34,52
TABLE II. Selected Variable for Black and White Adults Aged 60 to 79 Years With Treated or Untreated














NHANES, No. (%)a 95 (9.4%) 174 (11.0%) 73 (6.6%) 184 (10.6%)
US population, No. 293,107 2,273,139 205,799 2,174,586
Age, y 67.80.6 68.60.5 66.20.7 67.60.4
Male, % 38.65.6 40.43.5 46.27.8 46.64.4
BMI, kg/m2 29.20.6 28.80.6 28.00.9 28.00.6
BMI, kg/m2
<25, % 24.85.0 23.34.0 39.47.3 33.04.0
≥30, % 38.34.9 35.24.8 34.25.8 31.85.3
Visits per y, %
<2 12.73.7 14.82.8 44.96.3 31.53.8
≥2 87.33.7 85.22.8 55.16.3 68.53.8
Uninsured, % 11.03.6 4.71.9 17.15.0 5.91.9
SBP, mm Hg 156.91.6 151.90.8b 152.91.1 151.81.1
DBP, mm Hg 72.41.2 72.20.8 72.31.4 73.70.8
Aware, % 100.00 100.00 28.65.6 15.13.3c
BP control <150/<90 mm Hg, % 44.04.4 54.03.8 49.46.3 52.64.7
Non-HDL, mg/dL, % 145.34.1 147.93.8 148.55.0 159.72.9
Cholesterol medication, % 36.55.6 45.23.4 15.64.3 19.93.4
Smoker, % 13.13.1 8.22.2 23.76.1 16.03.3
CVD, % 18.63.5 20.93.8 8.63.4 9.72.3
ASCVD10 y, % 22.00.9 21.30.9 16.41.0 17.80.7
Abbreviations: ASCVD10 y, estimated 10-year risk for atherosclerotic cardiovascular disease; BMI, body mass index; BP, blood pressure; CVD,
cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL, high-density lipoprotein; SBP, systolic blood pressure. Data in italics
indicate relative standard errors >30%, which exceed National Health and Nutrition Examination Survey (NHANES) reporting guideline limits. These
results are provided for information only and not statistical comparisons. aPercentage of hypertensive adults in race group (denominator from Table II).
bP<.05. cP<.01 blacks vs whites within treated or untreated group.
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Recommendation 2: Continue antihypertensive ther-
apy in black adults of African descent aged 60 to
79 years without DM/CKD when treatment results in
an SBP <140 mm Hg and is well tolerated.
We are concerned the corollary to the first recom-
mendation in the 2014 Hypertension Guideline is being
overlooked and that treatment is being reduced for
patients in this group. In the 2010 ISHIB consensus
statement, the recommended goal clinic BP for black
adults of African descent without DM/CKD was <135/
<85 mm Hg.3 Given BP variability,52 average clinic BP
will be <135/<85 mm Hg in the majority of adults 60 to
79 years who have controlled BP to <140/<90 mm Hg
on most visits.
Recommendation 3: Initiate treatment for SBP
≥140 mm Hg and treat to a goal of <140 mm Hg in
black adults 60 to 79 years of African descent who do
not have DM/CKD.
This recommendation is based on expert opinion
informed by studies included in Table S2,32–35 several
guideline statements (Table S3),36–40 and other trials
and reports.9–11,47,51,53–55
Another potentially important point to consider is
that clinical trials in isolated systolic hypertension did
not enroll a representative sample of older adults.
Nearly a quarter million adults were screened in Systolic
Hypertension in the Elderly Program (SHEP) to enroll
approximately 4700.25 Adults in SHEP, including the
placebo and active intervention groups, had significantly
greater longevity than an age-matched control popula-
tion.56 Moreover, adults in the Hypertension in the Very
Elderly Trial (HYVET) did not have dementia, require-
ment for nursing care, heart failure requiring treatment
with antihypertensive medication drug classes, recent
cardiovascular events, or major renal impairment.29
Thus, guidance provided by ISHIB and other groups are
recommendations based on data in relatively healthy
elderly populations and not mandates. Clinicians are
encouraged to use their judgment in deciding when to
implement guideline recommendations for an individual
patient.
PERSPECTIVE
ISHIB trustees commend health-care professionals
across the United States who provide care for African
American adults aged 60 to 79 years with hypertension.
Mean SBP for this high-risk group is <140 mm Hg,
which has contributed to the decline in cardiovascular
disease. More than half of all African American adults
aged 60 to 79 years with hypertension also have
diabetes and/or CKD compared with two in five white
adults. Hypertension control to <140/<90 mm Hg in
this group was documented in well over half and similar
to their Caucasian counterparts. However, among black
adults with hypertension in this age group who did not
have diabetes or CKD, BP control to <140/<90 mm Hg
was observed in fewer than half and was lower than in
white adults. Of particular concern, in both black and
white adults with hypertension in the absence of
diabetes or CKD and BP ≥140/<90 mm Hg, fewer than
30% were aware of their hypertension and more than
30% reported only 0 to 1 health-care visits in the
previous year. Based on expert opinion, ISHIB
recommends a treatment goal of <140/<90 mm Hg to
improve cardiovascular outcomes for black adults aged
60 to 79 years, including those without diabetes or
CKD. Broad-based efforts are required in older adults
without diabetes or CKD to raise awareness of isolated
systolic hypertension and engage them in the treatment
and control of their hypertension.
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